Results 251 to 260 of about 433,063 (359)
Engineering Bacteria as Living Therapeutics in Cancer Therapy
Through synthetic biology approaches, natural bacteria can be genetically programmed into multifunctional living therapeutics. These engineered bacteria are capable of secreting anti‐tumor factors, displaying tumor‐associated antigens on their surface, or undergoing programmed self‐lysis to release therapeutic cargo.
Jiangfeng Chen+6 more
wiley +1 more source
Antimicrobial Drug-Resistant Shiga Toxin-Producing Escherichia coli Infections, Michigan, USA. [PDF]
Mukherjee S+6 more
europepmc +1 more source
A Study on Origin and Properties of Escherichia coli as Pathogen for Urinary Tract Infection
Kazuo Itoh
openalex +2 more sources
Biodegradable Medical Implants: Reshaping Future Medical Practice
Biodegradable medical implants are transforming future healthcare by providing sustainable, biocompatible solutions that eliminate secondary removal procedures, enhancing patients’ physical and psychological comfort, and reducing economic burdens.
Bo Xia+4 more
wiley +1 more source
Interactions between polymorphonuclear leucocytes, Bacteroides sp, and Escherichia coli: their role in the pathogenesis of mixed infection. [PDF]
W. A. C. Vel+4 more
openalex +1 more source
FOXM1 maintains mitochondrial bioenergetic function by inhibiting MKRN1‐mediated ubiquitination of LKB1 in cardiomyocytes. Loss of FOXM1 in cardiomyocytes results in upregulation of MKRN1, which enhances LKB1 ubiquitination and disrupts AMPK signaling and energy metabolism pathways. Conversely, FOXM1 overexpression preserves mitochondrial bioenergetics
Shuai Song+17 more
wiley +1 more source
Biocompatible Mesoporous Materials for Bone Therapy
Biocompatible mesoporous materials (BMMs), characterized by high specific surface area, tunable pore size, different shapes and structures, and multidimensional functionalized modifications, have revolutionary applications in treating bone‐related diseases.
Biao Yu+6 more
wiley +1 more source
Repositioning Antimicrobial Peptides Against WHO‐Priority Fungi
The growing burden of drug‐resistant fungal infections, driven by pathogens such as Candida auris, Cryptococcus neoformans, and Aspergillus fumigatus, underscores the urgent need for novel antifungal therapies. This review explores antimicrobial peptides as promising agents with membrane‐disruptive activity, immunomodulatory properties, and delivery ...
Cesar Augusto Roque‐Borda+12 more
wiley +1 more source